证券日报网2月24日讯 ，瑞丰高材在接受调研者提问时表示，公司子公司瑞丰生物主要从事合成生物材 料的开发，在聚乳酸、丁二酸、右旋糖酐等产品领域有一定的技术积累。其中，右旋糖酐已正常对外销 售，正进一步积极开拓市场，下游用于制备动物补铁剂右旋糖酐铁。2026年，公司将进一步扩大右旋糖 酐的产能，并进一步开拓销售市场，但短期对业绩无明显影响。未来规划方面，公司将通过自研与外部 技术合作的模式扩展产品品类，逐步进行规模化落地。 （文章来源：证券日报） ...

瑞丰高材（300243.SZ）2月13日在投资者互动平台表示，公司子公司瑞丰生物主要从事合成生物材料的 开发，在聚乳酸、丁二酸、右旋糖酐等产品领域有一定的技术积累。其中，右旋糖酐已正常对外销售， 正进一步积极开拓市场，下游用于制备动物补铁剂右旋糖酐铁。2026年，公司将进一步扩大右旋糖酐的 产能，并进一步开拓销售市场。公司将以全资子公司瑞丰生物为主体，继续通过自研、与成熟技术成果 开展合作等方式丰富合成生物产品的品类。努力做强做大公司合成生物材料业务。公司合成生物相关产 品业务尚处于起步阶段，短期内不会对公司业绩产生较大影响，敬请广大投资者注意投资风险。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：公司对生物制造的长期发展规划是什么？未来如何实 现规模化发展？ ...

Core Insights - The synthetic biology industry is experiencing significant growth, with the global market expected to reach $24.58 billion in 2023 and potentially exceed $100 billion by 2032, while China's market is projected to surpass $70 billion this year [3][9][10] - The industry is transitioning from a story-driven phase to a focus on profitability and commercial viability, marking a maturation process [3][32] - The integration of AI into synthetic biology is reshaping the entire research and production process, enhancing efficiency and reducing development cycles [24][25] Market Overview - The global synthetic biology market was valued at approximately $14 billion in 2022 and is projected to grow to $38.7 billion by 2027 [9][10] - China's synthetic biology market has shown a steep growth trajectory, increasing from $9 million in 2016 to an estimated $70 billion in 2023 [10][11] - The A-share market features over 160 synthetic biology concept companies, collectively valued at around $1.69 trillion, indicating a robust ecosystem [17] Investment Trends - Investment in synthetic biology is shifting from a broad approach to a more targeted strategy, focusing on companies with clear commercialization pathways [11][12] - In 2025, the capital flow in the synthetic biology sector is characterized by a significant concentration in the healthcare field, with major investments in companies like Yikole Biotechnology [11][12] - The beauty sector is emerging as a hot investment area, with over 46.5% of financing events in the cosmetics field related to synthetic biology [11] Policy and Regulatory Environment - The Chinese government is actively supporting the synthetic biology industry through comprehensive policies, including the "14th Five-Year Plan" which emphasizes biomanufacturing [14][33] - Policies are being implemented to enhance the development of biomanufacturing capabilities, with a goal to establish over 20 pilot platforms by 2027 [31][33] Industry Dynamics - The synthetic biology sector is witnessing a diversification of applications beyond healthcare, extending into chemicals, materials, and agriculture [7][9] - The healthcare segment remains the largest market, with a projected size of $10.3 billion by 2027, driven by innovations like CAR-T therapies [17][18] - The food and agriculture sectors are expected to see the fastest growth rates, with annual compound growth rates of 45.4% and 56.4% respectively from 2022 to 2027 [18] Technological Innovations - AI is becoming a core driver in synthetic biology, moving from a supportive role to a central engine in research and production processes [24][25] - Significant advancements in AI and synthetic biology are enabling the design of complex biological systems and enhancing production efficiency [24][25] - Companies are leveraging AI to optimize fermentation processes and improve product quality, demonstrating the practical applications of these technologies [26][27] Challenges and Future Outlook - The industry faces challenges in scaling from laboratory results to commercial production, with a significant drop in success rates without pilot testing [29][31] - The need for a robust ecosystem that supports innovation and commercialization is critical for overcoming existing barriers [32][33] - The future of the synthetic biology industry is promising, with expectations for continued growth driven by technological advancements and supportive policies [32][33]

【SynBioCon】 获 悉， 近日， 山东大学微生物改造技术全国重点实验室祁庆生团队 在《 Metabolic Engineering 》上发表题为" Engineered Non-Canonical Reductive TCA Pathway Drives High-Yield Succinic Acid Biosynthesis in Yarrowia lipolytica "的研究论文。博士研究生 陶慧琳为论文第一作者，祁庆生教授和崔志勇副研究员为通讯作者。山东大学微生物改造技术全国重点实验室为第一完成单位和通讯作者单位。 C4-二羧酸是一类具有应用价值的化合物，广泛应用于医药、化工、食品等领域。其中，丁二酸作为多种高价值化学品的平台化合物，可以合成1,4 - 丁二醇、四氢呋喃、聚丁二酸丁二醇酯等产品，在化工以及塑料降解领域具有重要价值。解酯耶氏酵母凭借优异的耐酸性以及对低成本原料的兼容性， 成为丁二酸生物合成的潜力宿主。还原TCA（rTCA）途径由于合成路径短、理论转化率高是目前C4-二羧酸合成的主要途径。但酵母不存在天然的 rTCA途径，异源引入后胞质内NADH不足以满足rTCA途径合成丁二酸所 ...

Investment Rating - The investment rating for the company is "Hold" [5] Core Views - The company reported a revenue of 2.2 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 43%. However, the net profit attributable to the parent company was 170 million yuan, a decrease of 1.3% year-on-year [1] - Despite weak price performance of main products, the increase in sales volume has contributed to revenue growth. The average price of valine was 14 yuan/kg, down 4.5% year-on-year, while tryptophan and arginine saw price declines of 29% and 25% respectively [2] - The company is optimizing product resource allocation and enhancing sustainable profitability through increased R&D investment in new products, including biobased materials [2][3] - The establishment of an AI digital laboratory aims to integrate AI technology into synthetic biology and company management, enhancing operational efficiency [3] - The company plans to issue overseas shares and list on the Hong Kong Stock Exchange to support its globalization strategy and improve capital structure [3] Financial Summary - For 2025, the company expects net profits of 230 million yuan, 310 million yuan, and 360 million yuan for the years 2025, 2026, and 2027 respectively, with adjustments made due to declining prices of some main products [3] - The projected revenue for 2025 is 3.16 billion yuan, with a growth rate of 44.98% [4] - The company’s EBITDA for 2025 is estimated at 495.79 million yuan, with a P/E ratio of 42.63 [4][10] Product and Market Strategy - The company is advancing projects in biobased materials and has initiated technical upgrades to existing production facilities to allow flexible production of various products [2] - The R&D expenditure for the first three quarters of 2025 was 110 million yuan, reflecting a year-on-year increase of 17.58% [3]

Core Viewpoint - The article emphasizes the economic feasibility of converting non-grain biomass waste, such as straw, into high-value products through comprehensive innovation across the entire supply chain [2][4]. Group 1: Research and Development - Professor Jin Mingjie’s team at Nanjing University of Science and Technology has addressed key challenges in the biorefining process of lignocellulosic biomass, including high raw material collection and transportation costs, stringent pretreatment conditions, toxic byproducts, low bioconversion efficiency, and difficulties in lignin degradation [2]. - A novel pretreatment technology and biorefining system have been developed to solve critical issues in the biorefining process [2]. - The team has developed a high-solid enzymatic hydrolysis technology that achieves a fermentable sugar concentration exceeding 200 g/L, allowing for efficient fermentation of hydrolysate into products like cellulose ethanol, lactic acid, succinic acid, citric acid, and lipids without the need for washing or detoxification [2]. Group 2: Lignin Utilization - The research includes the analysis of lignin biodegradation pathways and the discovery of new lignin-degrading enzymes, employing a "biological funnel" strategy to construct multiple engineered strains for the efficient conversion of lignin into high-value products such as muconic acid and gallic acid [2]. Group 3: Company Formation and Impact - In 2024, Professor Jin Mingjie founded Suzhou Limi Biotechnology Co., Ltd. in Suzhou High-tech Zone, which has developed globally leading complete technologies with independent intellectual property rights, breaking through the industrialization bottleneck of converting non-grain biomass waste into high-value biochemical products [4]. - The establishment of this company is considered epoch-making in the field of biomass utilization [4]. Group 4: Industry Engagement - Professor Jin Mingjie is scheduled to present a report titled "Biorefining of Lignocellulosic Biomass Based on 'Sugar' Platform" at the 2025 Non-Grain Biomass High-Value Utilization Forum (NFUCon 2025) in Hangzhou, Zhejiang, from January 27 to 29, 2025, inviting industry participation for exchange [5].

Investment Rating - The investment rating for the company is "Buy" with expectations of a stock price increase of over 15% relative to the industry index in the next six months [5][20]. Core Viewpoints - The company is advancing its "Bio + AI" strategy to build a multi-dimensional product system, which includes amino acids, vitamins, and bio-based new material monomers. This diversification is expected to enhance profitability and growth potential as new products are gradually launched and technical upgrades are completed [9][10][11]. - The company reported a revenue of 1.489 billion yuan in the first half of 2025, a year-on-year increase of 46.54%, while the net profit attributable to the parent company was 115 million yuan, a decrease of 23.26% year-on-year [1][2]. Financial Performance Summary - **Revenue Growth**: The projected revenue for 2025 is 2.617 billion yuan, with a year-on-year growth rate of 20.1%. The revenue is expected to continue growing to 3.098 billion yuan in 2026 and 3.591 billion yuan in 2027 [1][11]. - **Net Profit**: The net profit attributable to the parent company is projected to be 240 million yuan in 2025, recovering to 298 million yuan in 2026 and 381 million yuan in 2027, with corresponding growth rates of 26.6%, 24.3%, and 27.6% respectively [1][11]. - **Profitability Ratios**: The return on equity (ROE) is expected to improve from 7.2% in 2024 to 12.2% in 2027, indicating a recovery in profitability [1][11]. - **Earnings Per Share (EPS)**: The EPS is projected to be 0.96 yuan in 2025, increasing to 1.19 yuan in 2026 and 1.52 yuan in 2027 [1][11]. Cash Flow and Financial Health - The net cash flow from operating activities in the first half of 2025 was 75 million yuan, a decrease of 9.93% year-on-year. The net cash flow from investing activities was -261 million yuan, an increase of 40.91% year-on-year, primarily due to reduced cash payments for fixed assets and intangible assets [3]. - The company’s cash and cash equivalents at the end of the period were 379 million yuan, a decrease of 3.63% year-on-year [3]. Market Conditions and Product Pricing - The overall gross profit margin for the first half of 2025 was 24.11%, a decline of 7.49 percentage points compared to the same period in 2024. This decline is attributed to rising costs of amino acids and vitamins, as well as a decrease in the prices of certain products [2][4]. - The price of L-alanine dropped approximately 42.86% from early 2025 to the end of June 2025, which has exerted pressure on the company's performance [4]. Strategic Initiatives - The company is focusing on enhancing its research and development capabilities, particularly in the integration of AI technology within its operations. This initiative aims to improve production efficiency and product quality, thereby supporting sustainable growth [10].

Core Viewpoint - The company has announced a delay in the "Malic Acid Co-production Tryptophan Project," extending the expected operational date from 2025 to October 2026 due to project implementation and investment progress considerations [5][6][7]. Fundraising and Investment Project Overview - The company raised approximately RMB 699.99 million through a private placement of 21,122,510 shares at RMB 33.14 per share, with net proceeds after expenses amounting to RMB 683.81 million [1][2]. - The total planned investment for the projects was adjusted from RMB 700 million to RMB 683.81 million, with specific allocations for projects detailed in a table [2][3]. Fund Usage and Project Status - As of June 30, 2025, the company has fully utilized the raised funds for the "Succinic Acid Co-production Valine/Inositol Project" and the "Malic Acid Co-production Tryptophan Project," with investment ratios exceeding 100% for both projects [4]. - The company has established a special account for the management of the raised funds, ensuring compliance with regulatory requirements [2][3]. Delay Reasons and Impact - The delay in the "Malic Acid Co-production Tryptophan Project" is based on the need for technical upgrades to production equipment and alignment with market demand [5][6]. - The company asserts that the delay will not affect the project's investment direction, implementation entity, or method, and it does not pose any risk to shareholder interests [6][7]. Approval and Compliance - The board of directors and the supervisory board have approved the delay, and the decision complies with relevant regulations and internal governance [7][8].

Core Viewpoint - The company has decided to postpone the completion date of the "Apple Acid Co-production Tryptophan Project" from 2025 to October 2026 due to actual construction progress and investment considerations [5][6][7]. Fundraising and Investment Project Overview - The company has successfully raised a net amount of RMB 683.81 million after deducting issuance costs of RMB 16.19 million, with all funds received by October 21, 2024 [1][2]. - The adjusted fundraising allocation for investment projects totals RMB 683.81 million, down from an initial plan of RMB 700 million [2][3]. Fund Usage and Project Status - As of June 30, 2025, the company has fully utilized the raised funds for the "Apple Acid Co-production Tryptophan Project" and the "Succinic Acid Co-production Valine/Inositol Project," with investment ratios exceeding 100% for both projects [5][6]. - The company has established a special account for the management of raised funds, ensuring compliance with regulatory requirements [2][3]. Delay Details - The postponement of the "Apple Acid Co-production Tryptophan Project" is based on market demand and technical upgrades to production equipment, with no changes to the project's investment direction or implementation [6][7]. - The company has confirmed that the delay will not adversely affect the normal operation of the company or the interests of shareholders, particularly minority investors [8]. Approval and Oversight - The decision to postpone the project has been approved by the company's board and supervisory committee, adhering to necessary regulatory procedures [8][9]. - The sponsor institution has conducted a thorough review and supports the decision, confirming that it aligns with relevant laws and regulations [8][9].

Investment Rating - The report maintains a "Buy" rating for the company [9][12]. Core Views - The company reported a revenue of 1.49 billion yuan for the first half of 2025, representing a year-on-year increase of 46.5%. However, the net profit attributable to shareholders decreased by 23.3% to 110 million yuan [2][6]. - In Q2 2025, the company achieved a revenue of 800 million yuan, which is a 55.6% increase year-on-year and a 16.7% increase quarter-on-quarter. The net profit for the same quarter was 60 million yuan, reflecting a year-on-year increase of 1.0% and a quarter-on-quarter increase of 24.9% [2][6]. - The company is focusing on optimizing product resource allocation and enhancing profitability through investments in bio-based new materials, particularly 1,3-propanediol [12][12]. - The company is advancing its projects systematically, with ongoing developments in various production facilities aimed at increasing output for products like tryptophan and L-valine [12][12]. - The company is leveraging AI technology in its research and development processes to enhance operational efficiency and product development [12][12]. - The company is recognized as a leading player in the bio-manufacturing sector, with high technical barriers for its products, and future growth in new product volumes is anticipated [12][12]. Financial Summary - The company expects net profits attributable to shareholders to reach 280 million yuan, 380 million yuan, and 640 million yuan for the years 2025, 2026, and 2027, respectively [12][12]. - The gross margin for Q2 2025 was reported at 23.9%, a decrease of 5.7 percentage points year-on-year and a decrease of 0.4 percentage points quarter-on-quarter [12][12].